Almeida JD, Berry DM, Cunningham CH Virology: coronaviruses. Nature. 1968; 220:(5168)

Coronaviruses—a general introduction. Centre for Evidence-Based Medicine. 2020. (accessed 25 August 2020)

Boulton J. Meningitis immunisation: challenges, successes and new developments. Br J Nurs.. 2013; 22:(1)20-25

Caddy S. Developing a vaccine for covid-19. BMJ. 2020; 369

Centers for Disease Control and Prevention. Vaccine testing and the approval process. 2020. (accessed 26 August 2020)

Clinical Trials Arena. China approves clinical trials of third COVID-19 vaccine candidate. Clinical Trials Arena. 2020. (accessed 25 August 2020)

Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020; 53:25-32

Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol.. 2019; 17:(3)181-192

Doms R. Chapter 3. Basic concepts, 3rd edn. In: Katze M, Korth M., Law G, Nathanson N (eds). London: Elsevier; 2016

Eli Lilly & Company Press Release. Lilly begins world's first study of a potential COVID-19 antibody treatment in humans. 2020. (accessed 25 August 2020)

European Centre for Disease Prevention and Control. Communicable disease threat report. Week 29, 12–18 July 2020. (accessed 25 August 2020)

Folegatti PM, Ewer KJ Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet.. 2020; 396:(10249)467-478 Clinical trials applications for Coronavirus (COVID-19). 2020. (accessed 25 August 2020)

Hotez PJ, Corry DB, Bottazzi ME. COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol.. 2020; 20:(6)347-348

Kim YC, Dema B, Reyes-Sandoval A. COVID-19 vaccines: breaking record times to first-in-human trials. NPJ Vaccines. 2020; 5

Mahase E. Covid-19: Russia approves vaccine without large scale testing or published results. BMJ. 2020; 370

Coronavirus disease 2019 (COVID-19): epidemiology, virology, and prevention. 2020. (accessed 25 August 2020)

Unnatural science. 1977. (accessed 25 August 2020)

Milken Institute. FasterCures and the fight against COVID-19. 2000a. (accessed 25 august 2020)

Milken Institute. COVID-19 vaccine tracker. 2020b. (accessed 25 August 2020)

Morrison M, Plotkin S. Chapter 19. Viral vaccines: Fighting viruses with vaccines, 3rd edn. In: Katze M, Korth M., Law G, Nathanson N (eds). London: Elsevier; 2016

National Institute of Health Research. Be part of research. 2020. (accessed 3 September 2020)

Public Health England. Chapter 1. Immunity and how vaccines work. 2018. (accessed 25 August 2020)

Seow J, Graham C, Merrick B Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. (Preliminary preprint article that has not been peer-reviewed and is yet to be evaluated.).: MedRxiv; 2020

UK Research and Innovation. Getting to know the new coronavirus. 2020. (accessed 25 August 2020)

Worldometer. COVID-19 coronavirus pandemic. 2020. (accessed 25 August 2020)

Zhou P, Yang X-L, Wang X-G A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579:270-273

Zhu FC, Guan XH, Li YH Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet.. 2020; 396:(10249)479-488

In search of a vaccine against COVID-19: implications for nursing practice

10 September 2020
Volume 29 · Issue 16


This article discusses the background to the current COVID-19 pandemic. The specific features of the causative pathogen (SARS-CoV-2) are outlined, together with a ‘whistlestop’ revision of immunological principles. The article goes on to discuss the principles and mechanisms of immunisation and the stages of vaccine development. The current situation in relation to the race to develop a vaccine against COVID-19 is incorporated and the immunological principles being adapted by the top contenders are outlined. These include new approaches based on genetic sequencing. Finally, the importance of understanding theoretical principles and the potential practical implications for nurses who will be at the coalface, reassuring patients and delivering vaccines, is addressed.

Every day the human body is exposed to a huge number of viruses. Although most are harmless, some, which are known as pathogenic virions, can cause disease. Virus particles come in various shapes and sizes and the individual characteristics, together with the characteristics of the individuals they infect, impact on their virulence, including their mode of spread. They also impact on the ability of the immune system to mount an effective and sustained response to prevent disease. When this is not possible, development of a robust, safe, and long-lasting vaccines is sought (Doms, 2016).

On 31 December 2019, a new coronavirus (SARS-CoV-2) was identified from ‘a cluster of pneumonia cases of unknown aetiology with a common source of exposure’. By 10 January 2020, its genome sequence was released to the world (Zhou et al, 2020). By the end of the same month, its emergence had been declared a Public Health Emergency of International Concern. On 7 February, the disease it causes was named COVID-19 (Coronavirus Infectious Disease 2019), and within 6 weeks had been declared a pandemic (European Centre for Disease Prevention and Control, 2020). It would be great to say that the rest is history but sadly it is not.

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content